These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

826 related articles for article (PubMed ID: 29250803)

  • 1. Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort.
    Tadbiri S; Peyrin-Biroulet L; Serrero M; Filippi J; Pariente B; Roblin X; Buisson A; Stefanescu C; Trang-Poisson C; Altwegg R; Marteau P; Vaysse T; Bourrier A; Nancey S; Laharie D; Allez M; Savoye G; Gilletta C; Gagniere C; Vuitton L; Viennot S; Aubourg A; Pelletier AL; Bouguen G; Abitbol V; Fumery M; Claudepierre P; Bouhnik Y; Amiot A;
    Aliment Pharmacol Ther; 2018 Feb; 47(4):485-493. PubMed ID: 29250803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Vedolizumab Treatment and Arthritis/Arthralgia in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
    Alves Halpern G; Gomes C; Thaytala Quintino Falcon B; Prigol Dalfovo M; De Carvalho Maia J; Brandão Oliveira D
    J Gastrointestin Liver Dis; 2024 Sep; 33(3):379-385. PubMed ID: 39348571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and Characteristics of Extra-intestinal Manifestations in a Large Cohort of Greek Patients with Inflammatory Bowel Disease.
    Karmiris K; Avgerinos A; Tavernaraki A; Zeglinas C; Karatzas P; Koukouratos T; Oikonomou KA; Kostas A; Zampeli E; Papadopoulos V; Theodoropoulou A; Viazis N; Polymeros D; Michopoulos S; Bamias G; Kapsoritakis A; Karamanolis DG; Mantzaris GJ; Tzathas C; Koutroubakis IE
    J Crohns Colitis; 2016 Apr; 10(4):429-36. PubMed ID: 26721936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease - a retrospective study.
    Livne-Margolin M; Ling D; Attia-Konyo S; Abitbol CM; Haj-Natour O; Ungar B; Ben-Horin S; Kopylov U
    Dig Liver Dis; 2023 Feb; 55(2):223-229. PubMed ID: 36241535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease.
    Fleisher M; Marsal J; Lee SD; Frado LE; Parian A; Korelitz BI; Feagan BG
    Dig Dis Sci; 2018 Apr; 63(4):825-833. PubMed ID: 29484571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Extra-intestinal manifestation of IBD in Veszprém county (of Hungary): results of a 25-years follow-up study].
    Lakatos L; Pandur T; Dávid G; Balogh Z; Küronya P; Tollas A; Lakatos PL
    Orv Hetil; 2003 Oct; 144(40):1965-75. PubMed ID: 14626638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The appearance of joint manifestations in the Swiss inflammatory bowel disease cohort.
    Hiller A; Biedermann L; Fournier N; Butter M; Vavricka SR; Ciurea A; Rogler G; Scharl M;
    PLoS One; 2019; 14(4):e0211554. PubMed ID: 31039159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of vedolizumab therapy on extraintestinal manifestations in patients with inflammatory bowel disease: A systematic review and meta-analysis.
    Zheng DY; Wang YN; Huang YH; Jiang M; Ma YN; Dai C
    J Gastroenterol Hepatol; 2024 Sep; 39(9):1745-1759. PubMed ID: 38740543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab.
    Dupré A; Collins M; Nocturne G; Carbonnel F; Mariette X; Seror R
    Rheumatology (Oxford); 2020 Nov; 59(11):3275-3283. PubMed ID: 32259251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adalimumab Reduces Extraintestinal Manifestations in Patients with Crohn's Disease: A Pooled Analysis of 11 Clinical Studies.
    Louis EJ; Reinisch W; Schwartz DA; Löfberg R; Robinson AM; Berg S; Wang AW; Maa JF; Huang B; Pappalardo B
    Adv Ther; 2018 Apr; 35(4):563-576. PubMed ID: 29516410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study.
    Ramos GP; Dimopoulos C; McDonald NM; Janssens LP; Hung KW; Proctor D; Ruggiero E; Kane S; Bruining DH; Faubion WA; Raffals LE; Loftus EV; Al-Bawardy B
    Inflamm Bowel Dis; 2021 Jul; 27(8):1270-1276. PubMed ID: 33165569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease: Prevalence, Presentation, and Anti-TNF Treatment.
    Greuter T; Bertoldo F; Rechner R; Straumann A; Biedermann L; Zeitz J; Misselwitz B; Scharl M; Rogler G; Safroneeva E; Ali RAR; Braegger C; Heyland K; Mueller P; Nydegger A; Petit LM; Schibli S; Furlano RI; Spalinger J; Schäppi M; Zamora S; Froehlich F; Herzog D; Schoepfer AM; Vavricka SR;
    J Pediatr Gastroenterol Nutr; 2017 Aug; 65(2):200-206. PubMed ID: 27801751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease.
    Dubinsky MC; Cross RK; Sandborn WJ; Long M; Song X; Shi N; Ding Y; Eichner S; Pappalardo B; Ganguli A; Wang A
    Inflamm Bowel Dis; 2018 Aug; 24(9):1876-1882. PubMed ID: 29668916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
    Plevris N; Chuah CS; Allen RM; Arnott ID; Brennan PN; Chaudhary S; Churchhouse AMD; Din S; Donoghue E; Gaya DR; Groome M; Jafferbhoy HM; Jenkinson PW; Lam WL; Lyons M; Macdonald JC; MacMaster M; Mowat C; Naismith GD; Potts LF; Saffouri E; Seenan JP; Sengupta A; Shasi P; Sutherland DI; Todd JA; Veryan J; Watson AJM; Watts DA; Jones GR; Lees CW
    J Crohns Colitis; 2019 Sep; 13(9):1111-1120. PubMed ID: 30768123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review.
    Chateau T; Bonovas S; Le Berre C; Mathieu N; Danese S; Peyrin-Biroulet L
    J Crohns Colitis; 2019 Dec; 13(12):1569-1577. PubMed ID: 31076751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn's disease.
    Barreiro-de-Acosta M; Lorenzo A; Domínguez-Muñoz JE
    Rev Esp Enferm Dig; 2012 Sep; 104(9):468-72. PubMed ID: 23130854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Features Focusing on Extraintestinal Manifestations in Japanese Patients with Inflammatory Bowel Diseases: Far East 1000.
    Ohta Y; Taida T; Kato J; Ogasawara S; Oyama Y; Mamiya Y; Nakazawa H; Horio R; Goto C; Takahashi S; Kurosugi A; Sonoda M; Shiratori W; Kaneko T; Yokoyama Y; Akizue N; Ishigami H; Koseki H; Okimoto K; Saito K; Saito M; Matsumura T; Nakagawa T; Masuya Y; Fukuda Y; Kitsukawa Y; Shimura H; Tsuyuguchi T; Kato N
    Digestion; 2023; 104(4):328-334. PubMed ID: 36893744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials.
    Feagan BG; Sandborn WJ; Colombel JF; Byrne SO; Khalid JM; Kempf C; Geransar P; Bhayat F; Rubin DT
    J Crohns Colitis; 2019 Jan; 13(1):50-57. PubMed ID: 30203005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extraintestinal manifestations in Crohn's disease and ulcerative colitis: results from a prospective, population-based European inception cohort.
    Isene R; Bernklev T; Høie O; Munkholm P; Tsianos E; Stockbrügger R; Odes S; Palm Ø; Småstuen M; Moum B;
    Scand J Gastroenterol; 2015 Mar; 50(3):300-5. PubMed ID: 25535653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry.
    Chaparro M; Garre A; Ricart E; Iborra M; Mesonero F; Vera I; Riestra S; García-Sánchez V; Luisa De Castro M; Martin-Cardona A; Aldeguer X; Mínguez M; de-Acosta MB; Rivero M; Muñoz F; Andreu M; Bargalló A; González-Muñoza C; Pérez Calle JL; García-Sepulcre MF; Bermejo F; Huguet JM; Cabriada JL; Gutiérrez A; Mañosa M; Villoria A; Carbajo AY; Lorente R; García-López S; Piqueras M; Hinojosa E; Arajol C; Sicilia B; Conesa AM; Sainz E; Almela P; Llaó J; Roncero O; Camo P; Taxonera C; Domselaar MV; Pajares R; Legido J; Madrigal R; Lucendo AJ; Alcaín G; Doménech E; Gisbert JP;
    Aliment Pharmacol Ther; 2018 Oct; 48(8):839-851. PubMed ID: 30281832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.